Innocoll

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 1 drug with upcoming expirations

Activity

Key Events

Feb 1, 2021FDAMarcaine — POSIMIR

Aug 28, 2020FDAMarcaine — XARACOLL

Jun 16, 2017TrialSafety, Tolerability, PK, and Analgesic Effect of INL-001 in Children Following Open Inguinal Hernia Repair

Jun 2, 2017TrialPharmacokinetics, Relative Bioavailability and Safety of INL-001 Compared to Marcaine After Open Hernioplasty

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

6 patent groups across drugs · Source: FDA Orange Book

DrugExpires

MarcaineMay 20, 2029 MarcaineJan 9, 2033 Marcaine16 patentsJan 12, 2041 MarcaineMar 17, 2042 Marcaine2 patentsFeb 2, 2043 Marcaine4 patentsJul 2, 2044

Regulatory

Regulatory Timeline

19823 events

FDAJan 1

Marcaine — BUPIVACAINE HYDROCHLORIDE

Application NDA018053 (NDA)

FDAJan 1

Marcaine — MARCAINE HYDROCHLORIDE

Application NDA016964 (NDA)

FDAJan 1

Marcaine — SENSORCAINE

Application NDA018304 (NDA)

19841 event

FDAMay 4

Marcaine — MARCAINE

Application NDA018692 (NDA)

19921 event

FDASep 3

Marcaine — BUPIVACAINE HYDROCHLORIDE KIT

Application NDA019978 (NDA)

20111 event

FDAOct 28

Marcaine — EXPAREL

Application NDA022496 (NDA)

20201 event

FDAAug 28

Marcaine — XARACOLL

Application NDA209511 (NDA)

20211 event

FDAFeb 1

Marcaine — POSIMIR

Application NDA204803 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)